Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
Telix Pharmaceuticals Limited is experiencing growth in the radiopharmaceutical sector. The company reported a Q1 revenue of $230 million and reaffirmed its fiscal year 2026 guidance. Its progress in pipeline development and partnerships is contributing to its positive momentum.
- ▪Telix Pharmaceuticals Limited reported a Q1 revenue of $230 million, which is an 11% increase quarter-over-quarter.
- ▪The company has reaffirmed its fiscal year 2026 guidance, expecting revenue between $950 million and $970 million.
- ▪Telix is focused on advancing its pipeline and forming partnerships to enhance its market position.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906204-telix-pharmaceuticals-psma-radiopharmaceutical-player-is-revving-up"},"author":{"@type":"Person","name":"Jonathan…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
